title: [Eosinophilic gastroenteritis and colitis in pediatric patients: Increasingly frequent diseases].
abstract: Eosinophilic gastrointestinal disorders are a heterogeneous group of disorders characterized by no specific digestive symptoms associated with dense eosinophilic inflammation of the gastrointestinal tract in the absence of known causes for such tissue eosinophilia. Among these diseases, eosinophilic gastroenteritis (EGE) and colitis (EC) are less common than esophagitis, but their incidence and prevalence have been increasing over the past decade due in part to increased disease recognition. The exact pathophysiology is not clear: EGE and EC are immune-mediated diseases implicating adaptive T-helper cell type 2 immunity. According to the site of eosinophilic infiltration, there is a wide spectrum of digestive symptoms ranging from food refusal, nausea, vomiting, abdominal pain, weight loss, gastrointestinal bleeding (anemia), protein loosing enteropathy, ascites, bowel obstruction or perforation for EGE and diarrhea ± bleeding for CE. Endoscopic lesions are not specific: friability, erythematous mucosa with superficial erosions, or ulceration is often observed. Histologically, markedly increased numbers of mucosal eosinophils are seen in biopsy specimens. However, no standards for the diagnosis of EGE or CE exist and few findings support the diagnosis: intraepithelial eosinophils, eosinophil crypt abscesses, and eosinophils in muscularis mucosa and/or submucosa. Other organs are not involved. The other causes of tissue eosinophilia (infections, inflammatory bowel diseases) should be excluded. Food allergy appears to play a central role in driving inflammation in EGE and CE, as evidenced by symptomatic improvement with initiation of food exclusion or elemental diets. Dietary treatment should be the first therapeutic option in children. If the elimination diet fails, corticosteroids are currently the best characterized treatment but appropriate duration is unknown and relapses are frequent. In severe forms, immunomodulators or biologic agents (anti-IL5, anti-IgE, or anti-TNFa) can potentially play a role in the treatment of EGE and CE.
authors.affiliation: Service de nutrition et gastroentérologie pédiatriques, hôpital Trousseau, AP-HP, 26, avenue du Dr-Arnold-Netter, 75571 Paris cedex 12, France. Electronic address: julie.lemale@trs.aphp.fr.
authors.forename: J
authors.initials: J
authors.lastname: Lemale
authors.affiliation: Service d'anatomo-pathologie, hôpital Trousseau, AP-HP, 26, avenue du Dr-Arnold-Netter, 75571 Paris cedex 12, France.
authors.forename: L
authors.initials: L
authors.lastname: Dainese
authors.affiliation: Service de nutrition et gastroentérologie pédiatriques, hôpital Trousseau, AP-HP, 26, avenue du Dr-Arnold-Netter, 75571 Paris cedex 12, France.
authors.forename: P
authors.initials: P
authors.lastname: Tounian
mesh_terms: D003092:Colitis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D003663:Decision Trees; D004751:Enteritis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D004802:Eosinophilia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D005756:Gastritis / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D006801:Humans